MedTrace Logo

Positron Emission Tomography (PET) Study With (11C)Flumazenil to Determine Central GABAA Receptor Occupancy of AZD7325

NCT00681720 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2008-08-21

No results posted yet for this study

Summary

The study is carried out in order to determine the relationship between the dose of AZD7325 and the blood concentration of AZD7325, and to investigate to which extent AZD7325 binds to the GABAA receptors.

Conditions

Interventions

DRUG

AZD7325

Single dose of oral solution or capsule. 3 times per subject.

DRUG

Radioligand (11C) flumazenil

Single dose of i.v solution. 4 times per subject. (3 times together with AZD7325)

Sponsors & Collaborators

Principal Investigators

  • Bo Fransson · AstraZeneca Clinical Pharmacology Unit, Stockholm, Sweden

  • Eva Taavo · AstraZeneca R&D, Study Delivery, Clinical Development, Södertälje, Sweden

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2008-07-31
Completion
2008-07-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00681720 on ClinicalTrials.gov